|
Silence Therapeutics plc (SLN) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Silence Therapeutics plc (SLN) Bundle
Gain insight into your Silence Therapeutics plc (SLN) valuation analysis with our sophisticated DCF Calculator! Loaded with real SLN data, this Excel template enables you to adjust forecasts and assumptions, allowing you to accurately calculate the intrinsic value of Silence Therapeutics plc (SLN).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.4 | 16.8 | 23.6 | 34.3 | 58.4 | 95.8 | 157.3 | 258.1 | 423.5 | 695.0 |
| Revenue Growth, % | 0 | 126.59 | 40.97 | 44.99 | 70.47 | 64.11 | 64.11 | 64.11 | 64.11 | 64.11 |
| EBITDA | -48.0 | -61.3 | -64.6 | -67.2 | -66.1 | -95.8 | -157.3 | -258.1 | -423.5 | -695.0 |
| EBITDA, % | -648.46 | -365.86 | -273.61 | -196.17 | -113.25 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .7 | .6 | .7 | .7 | .8 | 3.6 | 5.8 | 9.6 | 15.7 | 25.8 |
| Depreciation, % | 9.05 | 3.44 | 2.75 | 1.96 | 1.37 | 3.72 | 3.72 | 3.72 | 3.72 | 3.72 |
| EBIT | -48.6 | -61.9 | -65.3 | -67.9 | -66.9 | -95.8 | -157.3 | -258.1 | -423.5 | -695.0 |
| EBIT, % | -657.51 | -369.3 | -276.37 | -198.13 | -114.62 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 50.6 | 99.3 | 96.0 | 72.9 | 198.9 | 95.8 | 157.3 | 258.1 | 423.5 | 695.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 39.6 | 11.5 | 23.4 | .3 | 36.3 | 63.4 | 104.0 | 170.6 | 280.0 | 459.5 |
| Account Receivables, % | 534.88 | 68.36 | 99.09 | 0.89852 | 62.2 | 66.11 | 66.11 | 66.11 | 66.11 | 66.11 |
| Inventories | 2.0 | .0 | -22.2 | .0 | .0 | -12.8 | -21.0 | -34.4 | -56.4 | -92.6 |
| Inventories, % | 27.23 | 0 | -93.86 | 0 | 0 | -13.33 | -13.33 | -13.33 | -13.33 | -13.33 |
| Accounts Payable | 3.1 | 5.5 | 4.3 | 3.5 | 5.0 | 21.4 | 35.1 | 57.6 | 94.5 | 155.1 |
| Accounts Payable, % | 41.7 | 32.74 | 18.2 | 10.36 | 8.55 | 22.31 | 22.31 | 22.31 | 22.31 | 22.31 |
| Capital Expenditure | -.7 | -1.8 | -.6 | -.1 | -.3 | -4.5 | -7.3 | -12.0 | -19.7 | -32.4 |
| Capital Expenditure, % | -9.38 | -10.75 | -2.51 | -0.17734 | -0.48777 | -4.66 | -4.66 | -4.66 | -4.66 | -4.66 |
| Tax Rate, % | -1.9 | -1.9 | -1.9 | -1.9 | -1.9 | -1.9 | -1.9 | -1.9 | -1.9 | -1.9 |
| EBITAT | -43.9 | -53.2 | -55.8 | -58.4 | -68.2 | -85.8 | -140.8 | -231.1 | -379.2 | -622.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -82.4 | -21.9 | -46.7 | -57.6 | -102.3 | -84.6 | -161.0 | -264.3 | -433.7 | -711.7 |
| WACC, % | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,134.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -726 | |||||||||
| Terminal Value | -8,738 | |||||||||
| Present Terminal Value | -5,350 | |||||||||
| Enterprise Value | -6,485 | |||||||||
| Net Debt | -164 | |||||||||
| Equity Value | -6,321 | |||||||||
| Diluted Shares Outstanding, MM | 16 | |||||||||
| Equity Value Per Share | -401.57 |
What You Will Get
- Authentic Silence Therapeutics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Updates: Automatic recalculations to assess the impact of changes on Silence Therapeutics' fair value.
- Flexible Excel Template: Designed for quick edits, scenario analysis, and detailed forecasts.
- Efficient and Precise: Avoid the hassle of building models from scratch while ensuring accuracy and adaptability.
Key Features
- Customizable Research Inputs: Adjust essential parameters such as clinical trial timelines, market penetration rates, and cost structures.
- Instant DCF Analysis: Quickly computes intrinsic value, NPV, and other key financial metrics.
- High-Precision Estimates: Leverages Silence Therapeutics' (SLN) actual financial data for accurate valuation results.
- Effortless Scenario Testing: Easily explore various assumptions and analyze different outcomes.
- Efficiency Booster: Streamline the valuation process without the hassle of constructing intricate models from the ground up.
How It Works
- Step 1: Download the prebuilt Excel template featuring Silence Therapeutics plc (SLN) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Silence Therapeutics plc (SLN) intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create detailed reports.
Why Choose This Calculator?
- Designed for Experts: A sophisticated tool utilized by biostatisticians, CFOs, and healthcare consultants.
- Accurate Data: Silence Therapeutics plc’s (SLN) historical and projected financials are preloaded for precision.
- Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance makes the process straightforward.
Who Should Use This Product?
- Investors: Evaluate Silence Therapeutics’ valuation before making stock transactions.
- CFOs and Financial Analysts: Enhance valuation workflows and validate financial forecasts.
- Startup Founders: Understand the valuation methods applied to biotech firms like Silence Therapeutics.
- Consultants: Provide comprehensive valuation reports for clients in the healthcare sector.
- Students and Educators: Utilize current data to learn and teach valuation strategies in biotechnology.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations.
- Real-World Data: Silence Therapeutics plc’s (SLN) historical and projected financials preloaded for analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables providing clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.